Antibody

135개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved135 programs
AntibodyLimited DatastaleInstitut Cancerologie de l'OuestPhase 2

durvalumab (Imfinzi, SBRT + Durvalumab)

Node; Prostate; Bone Metastases · Node; Prostate

#NodeProstate#Antibody#Phase2#monoclonal-antibody#Node+3
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

SC0191 + Bevacizumab (SC0191 + Bevacizumab)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleAstraZenecaPhase 2

durvalumab (Imfinzi, Selumetinib + ZEN-3694 ± Durvalumab)

MPNST; NF1 · MPNST

#MPNST#Antibody#Phase2#monoclonal-antibody#NF1+1
Trials 1Status Recruiting
AntibodyLimited DatastaleElevation OncologyPhase 2

Seribantumab (Seribantumab)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#Antibody#Phase2#monoclonal-antibody#Elevation
Trials 1Status Discontinued
AntibodyLimited DatastaleSun Yat-sen UniversityPhase 2

Sindilizumab (Sindilizumab)

Colorectal Cancer Metastatic; Chemotherapy · Colorectal Cancer Metastatic

#ColorectalCancerMetastatic#Antibody#Phase2#monoclonal-antibody#Chemotherapy+1
Trials 1Status Recruiting
AntibodyLimited DatastaleInnoventPreclinical

pembrolizumab (Keytruda, MPA, Sintilimab or Pembrolizumab and medroxyprogesterone acetate, Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)/ megestrol acetate (MA))

Endometrial Cancer; Endometrioid Carcinoma · Endometrial Cancer

#EndometrialCancer#Antibody#Preclinical#monoclonal-antibody#EndometrioidCarcinoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleAmsterdam UMC, location VUmcPhase 2

Standard dose cetuximab (Standard dose cetuximab)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase2#monoclonal-antibody#Amsterdam
Trials 1Status Discontinued
AntibodyLimited DatastaleOslo University HospitalPhase 3

daratumumab (Darzalex, Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#monoclonal-antibody#Oslo
Trials 1Status Recruiting
AntibodyLimited DatastaleUMC UtrechtPhase 2

FTD-TPI and bevacizumab (Systemic treatment, Systemic treatment (FTD-TPI and bevacizumab))

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase2#monoclonal-antibody#UMC
Trials 1Status Recruiting
AntibodyLimited DatastaleTriumvira Immunologics, Inc.Phase 2

pembrolizumab (Keytruda, TAC01-HER2 plus pembrolizumab)

HER2 Positive Gastric Cancer; Metastatic HER2 Positive Gastroesophageal Junction Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#HER2PositiveGastricCancer+2
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 2

TAS-102+bevacizumab+local treatment (TAS-102+bevacizumab+local treatment)

Metastatic Colorectal Cancer (CRC) · Metastatic Colorectal Cancer (CRC)

#MetastaticColorectalCancerCRC#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Recruiting
AntibodyLimited DatastaleBeiGenePhase 2

Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed (Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed)

Non-squamous Non-small Cell Lung Cancer; EGFR Gene Mutation · EGFR

#EGFR#Antibody#Phase2#monoclonal-antibody#Non-squamousNon-smallCellLungCan+2
Trials 1Status Active
AntibodyLimited DatastaleEli LillyApproved

Treatment of Encorafenib & Binimetinib & Cetuximab (Treatment of Encorafenib & Binimetinib & Cetuximab)

Solid Tumors · Solid Tumors

#SolidTumors#Antibody#Approved#monoclonal-antibody#Eli
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

Trifluridine-tipiracil plus Bevacizumab Alone (Trifluridine-tipiracil plus Bevacizumab Alone)

Refractory Metastatic Colorectal Cancer · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RefractoryMetastaticColorectalCa+1
Trials 1Status Recruiting
AntibodyLimited DatastaleEli LillyPhase 2

Tunlametinib + Cetuximab β (Tunlametinib + Cetuximab β)

Lung Cancer (NSCLC) · Lung Cancer (NSCLC)

#LungCancerNSCLC#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Recruiting
AntibodyLimited DatastaleBeijing Biostar Pharmaceuticals…Phase 2

Utidelone combined with Bevacizumab (Utidelone combined with Bevacizumab)

Non-small Cell Lung Cancer Patients with Brain Metastases · Non-small Cell Lung Cancer Patients with

#Non-smallCellLungCancerPatientsw#Antibody#Phase2#monoclonal-antibody#Beijing
Trials 1Status Recruiting
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 2

Varlilumab (Varlilumab)

Metastatic Distal Bile Duct Adenocarcinoma; Metastatic Gallbladder Carcinoma · Metastatic Distal Bile Duct Adenocarcino

#MetastaticDistalBileDuctAdenocar#Antibody#Phase2#monoclonal-antibody#MetastaticGallbladderCarcinoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleCatalYm GmbHPhase 2

Visugromab (Visugromab)

Metastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor · Metastatic Non-Squamous Non-Small Cell L

#MetastaticNon-SquamousNon-SmallC#Antibody#Phase2#monoclonal-antibody#AdultSolidTumor+1
Trials 1Status Recruiting
AntibodyLimited DatastaleCatalYm GmbHPhase 2

recommended dose for expansion (Visugromab RDE, Visugromab RDE (recommended dose for expansion))

Metastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor · Metastatic Non-Squamous Non-Small Cell L

#MetastaticNon-SquamousNon-SmallC#Antibody#Phase2#monoclonal-antibody#AdultSolidTumor+1
Trials 1Status Recruiting
AntibodyLimited DatastaleMerus B.V.Phase 2

Zenocutuzumab (Zenocutuzumab)

Breast Cancer Metastatic · Breast Cancer Metastatic

#BreastCancerMetastatic#Antibody#Phase2#monoclonal-antibody#Merus
Trials 1Status Active

6 / 7 pages

← PreviousNext →